Talaris Therapeutics, Inc.
NASDAQ:TALS
2.72 (USD) • At close October 19, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 57.005 | 34.245 | 15.278 | 13.369 |
| General & Administrative Expenses
| 19.472 | 13.262 | 7.406 | 5.009 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 19.472 | 13.262 | 7.406 | 5.009 |
| Other Expenses
| 0 | 0 | 0 | 0 |
| Operating Expenses
| 76.477 | 47.507 | 22.684 | 18.378 |
| Operating Income
| -76.477 | -47.507 | -22.684 | -18.378 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.583 | -0.326 | -0.023 | 0.223 |
| Income Before Tax
| -73.894 | -47.833 | -22.707 | -18.155 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| -5.166 | 0.326 | 0.023 | -0.223 |
| Net Income
| -68.728 | -48.159 | -22.73 | -17.932 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -16.66 | -16.53 | -34 | -28.09 |
| EPS Diluted
| -16.66 | -16.53 | -34 | -28.09 |
| EBITDA
| -74.315 | -46.884 | -22.237 | -17.999 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |